X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (24) 24
humans (23) 23
index medicus (18) 18
female (16) 16
male (16) 16
aged (14) 14
oncology (14) 14
middle aged (12) 12
adult (10) 10
primary myelofibrosis - drug therapy (8) 8
prognosis (8) 8
aged, 80 and over (7) 7
myelofibrosis (7) 7
benzamides (6) 6
cancer (6) 6
imatinib mesylate (6) 6
pyrazoles - therapeutic use (6) 6
survival (6) 6
acute myeloid leukemia (5) 5
essential thrombocythemia (5) 5
international working group (5) 5
leukemia (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (5) 5
mutation (5) 5
pyrazoles - adverse effects (5) 5
ruxolitinib (5) 5
survival rate (5) 5
treatment outcome (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
azacitidine (4) 4
chemotherapy (4) 4
chronic myelogenous leukemia (4) 4
classification (4) 4
efficacy (4) 4
follow-up studies (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - genetics (4) 4
medicine & public health (4) 4
myeloproliferative neoplasms (4) 4
piperazines - therapeutic use (4) 4
primary myelofibrosis - mortality (4) 4
primary myelofibrosis - pathology (4) 4
protein kinase inhibitors - therapeutic use (4) 4
pyrimidines - therapeutic use (4) 4
quality of life (4) 4
remission induction (4) 4
safety (4) 4
spleen - pathology (4) 4
tyrosine kinase (4) 4
abridged index medicus (3) 3
acute myeloid-leukemia (3) 3
adults (3) 3
analysis (3) 3
anemia (3) 3
antineoplastic agents - therapeutic use (3) 3
available therapy (3) 3
care and treatment (3) 3
cml (3) 3
disorders (3) 3
dosage and administration (3) 3
immunology (3) 3
intensive chemotherapy (3) 3
international-working-group (3) 3
janus kinase 1 - antagonists & inhibitors (3) 3
janus kinase 2 - antagonists & inhibitors (3) 3
leukemia, myeloid, acute - pathology (3) 3
low-dose cytarabine (3) 3
lymphoma (3) 3
mutations (3) 3
patients (3) 3
philadelphia chromosome (3) 3
piperazines - pharmacology (3) 3
polycythemia-vera (3) 3
primary myelofibrosis - diagnosis (3) 3
protein kinase inhibitors - administration & dosage (3) 3
protein kinase inhibitors - adverse effects (3) 3
pyrimidines - pharmacology (3) 3
survival analysis (3) 3
therapy (3) 3
world-health-organization (3) 3
activating mutation (2) 2
adolescent (2) 2
aml (2) 2
anemia - chemically induced (2) 2
anemia - drug therapy (2) 2
anemia - etiology (2) 2
anemia - mortality (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
articles (2) 2
azacitidine - therapeutic use (2) 2
b-cells (2) 2
bcr-abl (2) 2
blast crisis (2) 2
blast crisis - drug therapy (2) 2
blood cells - pathology (2) 2
bone marrow (2) 2
bone marrow cells - pathology (2) 2
cd20-antigen (2) 2
cell activation syndromes (2) 2
chromosome aberrations (2) 2
clinical medicine (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Genes, Chromosomes and Cancer, ISSN 1045-2257, 11/2019, Volume 58, Issue 11, pp. 747 - 755
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2952 - 2952
Background: The Janus kinase (JAK) inhibitor ruxolitinib (RUX) is approved for the treatment of disease-related splenomegaly and symptoms in patients with... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4583 - 4583
Abstract BACKGROUND: Ruxolitinib (RUX) is a potent JAK1/JAK2 inhibitor that has demonstrated rapid and durable reductions in splenomegaly, improvements in... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 2310 - 2310
Abstract Survival (OS) in elderly patients with AML is poor. Azacitidine (AZA) prolongs OS in elderly patients even with >30% marrow (BM) blasts (Dombret, EHA,... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 59 - 59
Abstract BACKGROUND: Ruxolitinib (RUX) is a potent JAK1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms as... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5945 - 5945
Abstract Introduction: Prognosis of patients (pts) with high risk acute lymphatic leukemia (ALL) in first complete remission (CR) or ALL >CR1 is poor. For... 
Journal Article
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2019, Volume 98, Issue 12, pp. 2825 - 2827
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 167 - 167
Abstract Abstract 167 Background: In the ENESTnd study, nilotinib significantly reduced progression to accelerated phase/blast crisis (AP/BC) and demonstrated... 
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 4975 - 4975
Abstract Abstract 4975 Background The vast majority of mastocytosis patients carry the p.D816V activating point mutation in exon 17 leading to imatinib... 
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1420 - 1420
Introduction: Old age and unfavorable cytogenetics are well-established adverse prognostic factors for outcome in patients (pts) with AML. Recently,... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2945 - 2945
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by progressive bone marrow fibrosis, ineffective erythropoiesis, dysplastic... 
Journal Article
Journal Article
Genes, Chromosomes and Cancer, ISSN 1045-2257, 11/2019, Volume 58, Issue 11, pp. 747 - 755
Sequential genotyping for phenotype‐driver mutations in JAK2 (exon 14), CALR (exon 9), and MPL (exon 10) is recommended in patients with myeloproliferative... 
somatic mutations | JAK2 mutation | myelofibrosis | germline mutations | MPL mutation | noncanonical mutations | MYELOPROLIFERATIVE NEOPLASMS | DISORDERS | RISK | ESSENTIAL THROMBOCYTHEMIA | WORLD-HEALTH-ORGANIZATION | INTERNATIONAL WORKING GROUP | ACTIVATING MUTATION | ONCOLOGY | MYELOID NEOPLASMS | GENETICS & HEREDITY | TYROSINE KINASE JAK2
Journal Article
Genes, chromosomes & cancer, ISSN 1045-2257, 05/2019, Volume 58, Issue 11, pp. 747 - 755
Sequential genotyping for phenotype-driver mutations in JAK2 (exon 14), CALR (exon 9), and MPL (exon 10) is recommended in patients with myeloproliferative... 
Gene mutations | Genes | Genetic aspects | Phenotypes | Myelofibrosis | Pathogenesis | Neoplasms | Gene sequencing | Heterogeneity | Genotype & phenotype | Genotyping | Janus kinase 2 | Clusters | Mutation | Deoxyribonucleic acid--DNA | Genotypes | DNA sequencing
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 83 - 83
Abstract The heterogeneity of AML requires a personalized treatment strategy to achieve a high initial response and translate this response into long-term... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.